Results 131 to 140 of about 17,083,974 (282)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner   +14 more
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Other title: House Bill 2127 - Testimony on Behalf of the Citizens' Utility Ratepayer Board by David Springe, Consumer Counsel

open access: yes, 2009
application/pdf; "February 3, 2009."; Testimony before the Kansas Legislature, House Utilities Committee, presented by David Springe, Consumer Counsel, Citizens' Utility Ratepayer Board.Testimony in opposition to House Bill 2127. "Sections
Springe, David.
core  

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Other title: Senate Bill 265 - Testimony on Behalf of the Citizens' Utility Ratepayer Board by David Springe, Consumer Counsel.

open access: yes, 2009
application/pdf; "February 18, 2009."; Testimony before the Kansas Legislature, Senate Utilities Committee, presented by David Springe, Consumer Counsel, Citizens' Utility Ratepayer Board.Testimony in opposition to Senate Bill 265.
Springe, David.
core  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

Other title: House Bill 2019 - Testimony [of] Michael D. Lura on Behalf of the Citizens' Utility Ratepayer Board

open access: yes, 2003
application/pdf; "January 27, 2003."; Testimony before the Kansas Legislature, House Utilities Committee, presented by Michael D. Lura, Citizens' Utility Ratepayer Board.Testimony in opposition to House Bill 2019 "as being overly broad in ...
Lura, Michael D.
core  

Home - About - Disclaimer - Privacy